Dr Vineeta Tripathi
Dr Vineeta Tripathi is a senior drug development leader with over 15 years of experience advancing therapeutic programmes from discovery through clinical development across pharma, biotech, and academic environments. She holds a PhD in Genetics from the University of Nottingham and a BSc in Biochemistry and Biotechnology.
Dr Tripathi has led multi-million-pound, multi-site programmes at King’s College London, University College London, Boehringer Ingelheim, and Ipsen Bioinnovation, delivering multiple assets into clinical development, including two ophthalmology programmes evaluated across seven clinical trials. She is a co-inventor on 13 granted patents, reflecting a strong track record in innovation and asset progression.
Her industry experience includes leading strategic collaborations with global partners and supporting high-value ophthalmology and immuno-oncology programmes, including a VEGF–Ang2 bispecific nanobody progressed into late preclinical and clinical evaluation for Age-related Macular Degeneration.
Dr Tripathi brings deep expertise in antibody discovery and engineering, mechanism-of-action studies, and fit-for-purpose in vitro and in vivo models. As a Scientific Advisor, she provides CRO clients with strategic, translational insight to support robust study design, efficient decision-making, and de-risking of development programmes.